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Abstract Caspase-9 is an apoptosis initiator protease activated
as a response to the mitochondrial damage in the cytoplasmic
complex apoptosome. By £uorescence labelling of proteins, con-
focal microscopy and subcellular fractionations we demonstrate
that caspase-9 is in the cytoplasm of non-apoptotic pituitary
cells. The activation of apoptosis with rotenone triggers the re-
distribution of caspase-9 to mitochondria. Experiments using the
general caspase inhibitor z-VAD.fmk and the speci¢c caspase-9
inhibitor z-LEHD.fmk show that the caspase-9 redistribution is
a regulated process and requires the activity of a caspase other
than the caspase-9. We propose that this spatial regulation is
required to control the activity of caspase-9.
* 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Apoptosis is essential for controlling the quality and the
number of cells [1]. It has a crucial role in tissue development
and remodelling and, when deregulated, can result in cancer
and in neurodegenerative diseases [2]. An ideal tissue in which
to study these processes is the anterior pituitary, which is
subject to tissue remodelling under di¡erent physiological
conditions, such as physiological and psychological stresses,
pregnancy and weaning [3]. The anterior pituitary responds by
changing the secretory capacity of existing cells and by
changes in apoptosis and in cell division [4]. Intense regulation
of cell numbers may account also for the relatively high prev-
alence of pituitary tumors. Cell lines derived from pituitary
adenomas were used as the model to study apoptosis before,
e.g. AtT20 [5], GH3B6 [6] and MMQ [7]. Also, the heterozy-
gous mice with disrupted retinoblastoma gene ^ the best char-
acterized tumor suppressor gene ^ have pituitary tumors and
are extensively used for studying cancerogenesis [8^10]. We
studied di¡erentiated pituitary somatotrophs, which synthe-
size and secrete growth hormone. Like in the other pituitary
cells, the amount of growth hormone discharged from soma-
totrophs is regulated by numerous cellular signalling mecha-
nisms [11] and also by the number of secretory cells available
by apoptosis [12^14].
The central e¡ectors of apoptotic process are intracellular
cysteine proteases, the members of the caspase family [15^18].
Caspases are divided into initiator and e¡ector caspases. The
initiator caspases start the process of apoptosis by activating
the downstream e¡ector caspases. Caspase-9 is a central ini-
tiator caspase, triggered in a response to stimuli that damage
mitochondria, either directly, or by signals originating in the
other parts of the cells [19^22]. The irreversible activation of
caspase-9, which involves the cleavage of its zymogen procas-
pase-9, occurs in the cytoplasm through its binding to Apaf-1
and cytochrome c in the presence of dATP [23^25]. In some
cases, caspase-9 is also activated through cleavage by the oth-
er activated caspases, such as caspase-3 [26], caspase-8 [27]
and caspase-12 [20]. The activation of caspase-9 can thus ini-
tiate the apoptotic process, or amplify it if it has started al-
ready.
There is disagreement about the intracellular localization of
caspase-9 in the literature. It was reported to be in the mito-
chondria [28^30], in the nucleus [26,31] or in the cytoplasm
[30^33]. Since the main route of caspase-9 activation is
thought to be through the cytoplasmic Apaf-1 complex [23^
25], one would expect that procaspase-9 is transported to this
location in order to be activated.
Using immunocytochemistry, confocal microscopy and sub-
cellular fractionations we found that procaspase-9 is in the
cytoplasm in the non-apoptotic pituitary cells. We show that
after the induction of apoptosis by the application of rote-
none, caspase-9 becomes co-localized with mitochondria.
The redistribution of caspase-9 is inhibited in the presence
of z-VAD.fmk, a wide-range caspase inhibitor, whereas the
speci¢c inhibition of caspase-9 by z-LEHD.fmk does not af-
fect the shift of caspase-9 from cytoplasm to mitochondria.
An activated caspase, other than caspase-9, is therefore re-
quired for triggering the procaspase-9 redistribution to mito-
chondria in rotenone triggered apoptosis. Even the pro-
caspase-9 was reported to be proteolytically active [34,35].
We propose that the spatial regulation described here controls
the activity of caspase-9, since it a¡ects the local concentra-
tion, possibly dimerization, of the procaspase-9 or limits the
contacts of procaspase-9 with its targets in non-apoptotic
cells.
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2. Materials and methods
2.1. Construction of fusion protein Casp9E
A fragment containing human caspase-9 was ampli¢ed from ICE-
Lap6his pcDNA3 [36] with the primer pairs NPcasp9 (5P-ccc cgg tac
cgc cat gga cga ag-3P) and CPcasp9 (5P-ccc cgg atc ccg gtg gtg tga tgt
ttt aaa gaa aag-3P) by polymerase chain reaction (PCR). The PCR
fragment was introduced into KpnI and BamHI sites of a plasmid
pEGFP-N1 (Clontech). In the resulting £uorescent fusion protein
Casp9E, the caspase-9 and enhanced green £uorescent protein
(EGFP) moieties are linked by the peptide: HHRDPPVAT.
2.2. Cell cultures, transfection, subcellular fractionation and
immunocytochemistry
Primary cell cultures enriched with somatotrophs were isolated
from the anterior lobe of pituitary glands of adult male rats (Wistar,
200^300 g) as described by Ben-Tabou et al. [37]. Cells were placed on
poly-L-Lys-coated coverslips, incubated in a standard medium [37]
and 24 h later the DNA was introduced using Lipofectamine
PLUS1 reagent (Invitrogen), according to the manufacturer’s instruc-
tions. The cells were observed under a confocal microscope or were
labelled by immunocytochemistry. Mitochondria were labelled by 600
nM tetramethylrhodamine methyl ester (TMRM, Molecular Probes).
Whenever necessary, 30 or 300 WM rotenone was added for 2 h in a
humidi¢ed CO2 atmosphere at 37‡C. Apoptotic cells were detected by
the annexin V conjugate with the dye Alexa Fluor 568 (Molecular
Probes) according to the manufacturer’s instructions [38]. Subcellular
fractions were prepared from rat anterior pituitaries in N-(2-hydroxy-
ethyl) piperazine-NP-(2-ethanesulfonic acid) (HEPES)-based bu¡er as
is described by Werner and Neupert [39]. The samples were analyzed
by sodium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) and Western blotting and were detected by the same anti-
bodies as were used for immunocytochemistry.
The immunocytochemistry was performed using the standard pro-
tocol as described by the suppliers. The following antibodies were
used: anti-caspase-9 (Cell Signalling Technology, Inc.), anti-cyto-
chrome c (BD Biosciences) and the appropriate secondary antibodies
conjugated to £uorescent dyes Alexa Fluor 546 (red, Molecular
Probes) and Alexa Fluor 488 (green, Molecular Probes). The cover-
slips were mounted using Light Antifade Kit (Molecular Probes). For
double staining the two primary antibodies (raised in di¡erent species)
were added sequentially. Unspeci¢c labelling by antibodies was tested
by staining the cells with £uorescent secondary antibodies only.
2.3. Confocal microscopy and image analyses
The £uorescent images were collected using a Zeiss LSM 510 con-
focal microscope with an oil immersion objective (40U and the nu-
merical aperture 1.3). EGFP and the conjugate Alexa Fluor 488 were
excited by argon laser (at 488 nm). The £uorescence was collected
through the band pass ¢lter (505^530 nm). For excitation of the con-
jugate Alexa Fluor 546 the He/Ne laser with bandwidth of 543 nm
was used in combination with a long pass ¢lter, which cut o¡ the light
below 560 nm.
The images obtained were analyzed by the program written for
Matlab software (unpublished), which counted the numbers of green,
red and co-localized pixels for each image. We calculated the percen-
tages of co-localized pixels regarding to all pixels above the threshold.
Data were subjected to statistical analyses using unpaired, two-tailed
Student’s t-test for equal variances.
3. Results
3.1. Casp9E mimicks the intracellular distribution of the
endogenous caspase-9
We constructed a fusion protein between the caspase-9 and
the EGFP (Casp9E), then introduced it into pituitary soma-
totrophs, which produce growth hormone. Using an antibody
against the growth hormone, the cell cultures were checked to
contain about 80% of somatotrophs (not shown) [37].
The subcellular distribution of Casp9E was compared with
that of the endogenous caspase-9 by using £uorescently la-
belled antibody against caspase-9 (K-Casp9), which recognized
both the wild-type caspase-9 and its £uorescent counterpart
Casp9E. The images of the cells expressing the endogenous
caspase-9 were compared to the images of the cells expressing
both the endogenous caspase-9 and the £uorescent Casp9E
(Fig. 1A). The red £uorescence signals of the labelled
K-Casp9 antibody were similarly distributed in both types of
the cells. Thus, the intracellular distribution of Casp9E mim-
icks that of its wild-type counterpart within the cells.
The comparison of the emissions of endogenous caspase-9
and Casp9E was taken as an example of completely co-local-
ized markers (Fig. 1B). The green and the red £uorescence
signals were sequentially acquired, in order to prevent the
cross talk between the two channels. Co-localization of the
two markers appears yellow in confocal images. Appearance
of some green and red pixels in otherwise yellow overlaid
image is likely due to unequal intensities of the two £uores-
cent markers, inherent in £uorescent microscopy. The steric
hindrance of antibodies with attached labels was previously
Fig. 1. Casp9E mimicks the intracellular distribution of caspase-9.
Bar: 5 Wm. A: Localization of endogenous caspase-9 (3Casp9E)
and of the endogenous caspase-9 with Casp9E (+Casp9E) stained
with rabbit antibody against the caspase-9 moiety (K-Casp9). B:
The representation of complete co-localization of the two £uorescent
markers; green: Casp9E and red: K-Casp9. The level of co-localiza-
tion was in this cell 64%. The intensity pro¢les of the two £uores-
cence channels were measured along the straight line through the
center of the cell image parallel to the plane of the coverslip (blue
line).
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observed to contribute to the reduction of the antibody bind-
ing [40] and also may contribute to the small scatter of £uo-
rescence intensities.
The distribution of the two £uorescent markers was com-
pared by plotting their intensity pro¢les (Fig. 1B) and showed
that the intensities of both signals overlapped. The £uores-
cence intensities of the two channels were measured along
the straight line through the center of the cell images parallel
to the plane of the coverslips. The intensities of the two £uo-
rescent signals were normalized so that the intensity of each
covered the entire range of shades (0^255). The two adjacent
pixels were averaged to ¢lter out the noise.
We determined the degree of co-localization of the £uores-
cent signals of K-Casp9 and Casp9E on 20 cells from three
experiments. To avoid the bias due to subjective analyses, the
procedure was automated using a computer program (unpub-
lished), which counts the number of red, green and yellow, i.e.
co-localized, pixels for each cell. The intensities of the two
£uorescent signals were normalized for each cell in order to
compare the images. To be counted, the pixel intensity had to
be above the threshold, which was arbitrarily taken to be 20%
of the intensity of the brightest pixel of each image. The
number of co-localized pixels was expressed as the ratio be-
tween the co-localized pixels (yellow) and the number of all
£uorescent pixels of the cell image. For example, if half of the
pixels of each channel were co-localized in a cell, then the
percentage of co-localization equalled 33%. The average per-
centage of co-localized pixels from 20 £uorescent cells in the
case of perfectly co-localized markers Casp9E and K-Casp9
was 68S 3%.
In conclusion, the red £uorescence signals of the labelled
K-Casp9 antibody are equally distributed in the cells express-
ing only the wild-type caspase-9 and the cells expressing
both caspase-9 and Casp9E. Therefore, Casp9E is a suitable
marker for tracing the subcellular localization of the endoge-
nous caspase-9 in the rat pituitary cells.
3.2. Caspase-9 is localized in the cytoplasm of non-apoptotic
cells
The intracellular distribution of Casp9E appears punctate
(Fig. 1A), which may be a sign of its association with organ-
elles. We therefore compared the localization of caspase-9 to
that of Sec61, an integral protein of endoplasmic reticulum
[41], and to the integral protein of the mitochondrial inner
membrane Tim23 [42]. When the intracellular distribution of
the wild-type caspase-9 is compared to the localization of
EGFP-labelled Sec61 (Sec61E, Fig. 2A), the localization of
each marker is distinct. Likewise, the two £uorescence signals
do not overlap on the £uorescence intensity pro¢les. The de-
gree of co-localization of Sec61E and K-Casp9 is 38S 4% from
the analysis of 18 cells, which is considerably lower than in the
case of complete co-localization of the two markers (Fig. 1).
Therefore, the lack of association of caspase-9 with the ER is
re£ected also in this low degree of numerical co-localization;
this is a quantitative example of intracellular distribution of
the two unrelated £uorescent markers in the cell.
We then investigated the intracellular distribution of cas-
pase-9 in relation to the mitochondrial marker Tim23 by com-
paring the £uorescence signals of Casp9E and labelled anti-
bodies against Tim23 (K-Tim23, Fig. 2B). The two markers do
not appear co-localized, either in the whole cell images or
when the intensities of the two channels are plotted. The per-
Fig. 2. Caspase-9 is localized in the cytoplasm of non-apoptotic
cells. Bar: 5 Wm. A: Co-localization of the endogenous caspase-9
with the endoplasmic reticulum marker, Sec61 fused to EGFP
(Sec61E). There are two cells in the image, one of them labelled
with Sec61E (green). B: Co-localization of Casp9E with the endoge-
nous mitochondrial protein Tim23, labelled with speci¢c antibodies
(K-Tim23) was in the cell shown 22%. Two of the three cells in the
image are labelled with Casp9E.
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centage of co-localized pixels from 17 cells equals to 24S 3%.
These results indicate that at least a major part, if not all of
caspase-9 is in the cytoplasm of pituitary cells.
Caspase-9 was detected in the intermembrane space of mi-
tochondria in previous studies [28,29]. We therefore decided
to double check the intracellular localization of caspase-9 with
that of cytochrome c, the protein of the mitochondrial inter-
Fig. 3. Caspase-9 is not co-localized with mitochondria in non-apo-
ptotic cells. Bar: 5 Wm. A: The localizations of the endogenous cas-
pase-9 (K-Casp9) and of the endogenous cytochrome c (K-Cytc) was
in the cell shown 27%. B: The representation of the degree of co-lo-
calization of caspase-9 with several mitochondrial markers. (n : the
number of analyzed £uorescent images; *: PH0.01).
C
Fig. 4. The redistribution of caspase-9 from cytoplasm to mitochon-
dria after rotenone-induced apoptosis. The images of living cells la-
belled with Casp9E and the mitochondrial dye TMRM. 300 WM ro-
tenone was added for 2 h, although comparable results were
obtained by 30 WM rotenone incubated for 8 h. Bar: 5 Wm. A: Im-
ages of co-localization of caspase-9 and of mitochondria before and
after the addition of rotenone. The level of co-localization in the
presented cell was before rotenone application 28% and after 53%.
B: Images of co-localization of caspase-9 and of mitochondria after
the addition of rotenone with caspase inhibitors z-VAD.fmk and
z-LEHD.fmk. C: The percentage of co-localization (mean and stan-
dard error) of Casp9E and TMRM (*: PH0.01).
FEBS 27297 21-5-03 Cyaan Magenta Geel Zwart
M. Potokar et al./FEBS Letters 544 (2003) 153^159156
membrane space. The endogenous caspase-9 and the endoge-
nous cytochrome c were £uorescently labelled by secondary
antibodies: red for the caspase-9 and green for the cyto-
chrome c (Fig. 3A). Although both signals were of punctate
appearance, they did not overlap. The alternating peaks of the
red and the green £uorescence measured along the central
plane of optical slices con¢rmed distinct distributions of cas-
pase-9 and cytochrome c. The level of co-localized pixels from
the analysis of 10 cells was 29S 2%, similar to the co-localized
pixels of Casp9E with Tim23, Sec61 and cytochrome c (Fig.
3B). Hence caspase-9 was not localized within mitochondria
under our conditions. We thought that the di¡ering results
regarding the intracellular localization of caspase-9 may be
a consequence of di¡erent physiological states of the cells.
So we investigated whether the activation of apoptosis in£u-
enced the subcellular distribution of caspase-9.
3.3. Apoptosis-associated redistribution of caspase-9
At least some components of apoptosome, in which cas-
pase-9 is activated, are in di¡erent subcellular compartments.
These have to be delivered to the site of assembly of the ap-
optosome complex upon the induction of apoptosis. To study
whether the activation of apoptosis is associated with the re-
distribution of caspase-9, we monitored the subcellular local-
ization of Casp9E before and after triggering of apoptosis by
the application of rotenone. Mitochondria were labelled by
TMRM, which accumulates in the mitochondria, depending
on the mitochondrial membrane potential [43]. All £uorescent
cells exhibited TMRM-labelled mitochondria.
2 h after the cells were exposed to rotenone they had
no apparent morphological signs of apoptosis. Nevertheless,
about 75% of the cells labelled with Casp9E were labelled also
with the £uorescent conjugate of annexin V, an early marker
of apoptosis [38]. In contrast, about 25% of the cells express-
ing Casp9E without added rotenone were labelled with annex-
in V (not shown). The number of necrotic cells, determined by
staining the cells with the membrane impermeant nucleic acid
stain Sytox Green, accounted for less than 1% of annexin
V-labelled cells in either group of cells, with or without added
rotenone. Therefore, practically all of the annexin V-labelled
cells were apoptotic in our conditions. In conclusion, the
treatment with rotenone has induced apoptosis in these con-
ditions.
To follow the distribution of caspase-9 in living cells we
collected confocal images of the cells, which were transfected
with Casp9E and stained with TMRM. The cells were either
sham treated (control cells) or had had rotenone added 2 h
before the images were collected. Under the control condi-
tions, the caspase-9 was spread out throughout the cytoplasm
(Fig. 4A) as before (Fig. 2B). The degree of co-localization of
Casp9E with TMRM from 15 cells is 31S 4%, which is similar
to that of caspase-9 with other mitochondrial markers shown
before (Fig. 3C). The addition of dimethyl sulfoxide (DMSO)
in mock treatment did not in£uence the localization of cas-
pase-9, since the degree of co-localization in 11 cells was
30S 5%. In contrast, the mitochondria-speci¢c dye TMRM
and the £uorescent Casp9E appeared co-localized after the
triggering of apoptosis with rotenone in all cells studied and
was apparent also on the £uorescence intensity pro¢les (Fig.
4A). The percentage of co-localization between the Casp9E
and TMRM signi¢cantly increased from 31S 4 to 53S 3% in
comparison to the co-localization of the caspase-9 and mito-
chondria before and after the rotenone treatment, respec-
tively. The shift of caspase-9 from cytoplasm to mitochondria
after the rotenone-induced apoptosis was con¢rmed also by
subcellular fractionations (Fig. 5). This shift was detected 2 h
after the addition of rotenone, though all caspase was associ-
ated with mitochondria when the cells were disrupted 3 h after
the rotenone addition. The induction of apoptosis program
therefore resulted in redistribution of caspase-9 from cyto-
plasm to mitochondria.
3.4. The redistribution of caspase-9 is triggered by a caspase
other than caspase-9
There are two main pathways for caspase-9 activation:
through an autoactivation process in the apoptosome and
through activation by other types of caspases [20,23^27]. If
the initiation of apoptosis by rotenone involves the activation
of caspases before the activation of the caspase-9, the addition
of a general caspase inhibitor should prevent the caspase-9
redistribution. Indeed, the addition of z-VAD.fmk (100
WM), a general caspase inhibitor prevents the rotenone-in-
duced redistribution of caspase-9 (Fig. 4B). This is apparent
also from the intensity pro¢les of the two channels and from
the percentage of co-localization of 27S 2% from 15 cells.
We then tested whether a fraction of activated caspase-9
could trigger the redistribution of the rest of the caspase-9
in a mechanism of positive feedback loop. To investigate
this possibility, we triggered the apoptosis by rotenone in
the presence of z-LEHD.fmk, the speci¢c caspase-9 inhibitor
[44]. Surprisingly, the redistribution of caspase-9 was not pre-
vented in the presence of z-LEHD.fmk (Fig. 4B). This result is
also con¢rmed by analyses of the plotted pro¢les of £uores-
cence intensities and by the statistical analysis of the percent-
age of co-localization from 17 cells, which equals 46S 2%,
which is signi¢cantly higher in comparison to the case of
uninduced apoptosis (31S 4%) or that of rotenone-induced
apoptosis in the presence of z-VAD.fmk (27S 2%). The neg-
Fig. 5. Subcellular fractionations con¢rm the shift of caspase-9 from
cytoplasm to mitochondria after the rotenone-induced apoptosis.
Upper panels: The localization of caspase-9 without and with the
addition of 300 WM rotenone for 2 h (3rotenone, +rotenone, re-
spectively). Cell lysates (T), cytosolic (C) and mitochondrial frac-
tions (M) were labelled with polyclonal antibodies against caspase-9
(K-Casp9) and against the mitochondrial marker Tim23 (K-Tim23).
The lanes of the full-length caspase-9 (about 50 kDa) and of Tim23
(23 kDa) are presented. Lower panels: The shift of caspase-9 from
the cytosol to the mitochondria is complete when the cells are dis-
rupted 3 h after the addition of rotenone.
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ative result of z-LEHD.fmk treatment on caspase-9 redistri-
bution might have occurred due to the inactive z-LEHD.fmk
preparation, therefore we checked the number of rotenone-
induced apoptotic cells in the presence of z-LEHD.fmk. The
numbers of apoptotic cells were expressed as the percentage of
the numbers of annexin V-labelled cells in the presence and in
the absence of inhibitor, taking the value of apoptotic cells in
the presence of rotenone only as 100%. In the presence of
z-LEHD.fmk the percentage of apoptotic cells was signi¢-
cantly reduced to 46S 3%, which indicates that z-LEHD.fmk
was active in blocking apoptosis although it did not a¡ect the
redistribution of caspase-9. We conclude that the rotenone-
mediated shift of caspase-9 in the early steps of apoptosis
requires the activation of a caspase other than the caspase-9.
4. Discussion
We have demonstrated the redistribution of caspase-9 from
the cytoplasm to mitochondria in early stages of apoptosis in
rat pituitary cells. We found that the distribution of Casp9E
equalled to that of the endogenous caspase-9. Both proteins
appeared in the cytoplasm in a punctate manner, which may
indicate that caspase-9 is in subcellular organelles. In previous
studies, caspase-9 was found in mitochondria [28,29], in the
cytosol [31,32], in the nucleus [26,31] or in combinations of
these organelles. This and the punctate appearance of the
caspase-9 signal prompted us to investigate whether caspase-
9 is localized in mitochondria. The labelling of endogenous
caspase-9 with endogenous cytochrome c by double immuno-
cytochemistry demonstrated that both signals appeared punc-
tate, but were intertwined. Therefore, caspase-9 is not within
mitochondria of non-apoptotic pituitary cells.
We cannot exclude the possibility of nuclear localization of
caspase-9. Nevertheless, unlabelled parts of the cells reminis-
cent of nuclei were frequently observed in confocal images
(Fig. 1). We concluded that caspase-9 is not appreciably lo-
cated in the nuclei of pituitary cells. Therefore, caspase-9 ap-
pears to be concentrated mainly in distinct structures within
the cytoplasm. Our results on the cytoplasmic localization of
caspase-9 are in agreement with those on the expression of
caspase-9 in 293 and Jurkat cell lines [31] and those from cell
fractionations of brain cortex [32]. In contrast, caspase-9 from
rat brain was localized in mitochondria by electron microsco-
py [29]. Caspase-9 was associated with mitochondria also at
confocal images of Rat-1 cell line and in isolated mitochon-
dria from Balb/c mice [28]. Possibly the di¡erences in local-
ization of caspase-9 are due to the di¡erent cell lines. Another
possibility is that the results di¡er because of di¡erent exper-
imental conditions. This may explain the con£icting results of
the two studies on the caspase-9 localization in rat brain
[29,32].
We demonstrate here the redistribution of caspase-9 from
cytoplasm to mitochondria in the early stages of apoptosis
before the apoptosis-associated morphology is observed. At
the same time, we can observe the early redistribution of
plasma membrane phosphatidylserine by annexin V labelling
in most cells, which is a general feature of apoptosis [38]. The
caspase-9 redistribution does not occur in the presence of a
general caspase inhibitor z-VAD.fmk, implying that the cas-
pase activity is necessary for triggering it. Since z-VAD.fmk is
a mechanism-based inactivator, it binds only to activated cas-
pases [35]. Which caspase is active before the redistribution of
caspase-9? One possibility is an initiator caspase other than
caspase-9, such as caspase-12 [20]. Another possibility is that
the apoptotic signal causes a small amount of already active
caspase-9 to trigger the redistribution of caspase-9 in a pos-
itive feedback loop mechanism. Caspase-9 di¡ers from other
members of caspase family in that even its procaspase form
can be proteolytically active [34,35].
The general caspase inhibitor z-VAD.fmk prevented the re-
distribution of caspase-9, although surprisingly the caspase-9-
speci¢c inhibitor z-LEHD.fmk did not. The possibility that
one peptide would bind to the caspase-9, while the other
would not can not be ruled out, though we think it is unlikely,
since both of them were used to inhibit caspase-9 in numerous
studies. Another explanation may be derived from considering
the co-relation between the intracellular redistribution of cas-
pase-9 with its activation. Since even the unprocessed mono-
mers of caspase-9 can be proteolytically active, perhaps the
most signi¢cant function of the apoptosome may be to irre-
versibly activate caspase-9. At least one other component of
the apoptosome, cytochrome c, is spatially divided from other
components of the apoptosome in the non-apoptotic cells. We
propose that caspase-9, like cytochrome c, is spatially sepa-
rated from the components of the apoptosome complex in
non-apoptotic cells. Its punctate distribution in the cytoplasm
implies that it is not freely spread around the cytosol, but it is
bound to discrete structures. The rearrangement of caspase-9
is triggered as a consequence of the activity of an as yet un-
determined caspase. The details of this triggering process and
the connection of caspase-9 redistribution to its activation
remain to be determined in further studies.
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